NPI registry status
Active
2026 NPPES data Rheumatology Physician NPI 1770899627 M.D.
Verify on CMS → Saira Bilal, M.D.
Rheumatology Physician in Washington, District of Columbia.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 6,377 in Rheumatology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
2K
Medicare Part D claims · 365 beneficiaries · Rheumatology Physician avg: 2K
Generic prescribing
84%
generic claims · 16% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$11.5K
193 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Saira Bilal, M.D. filed 1,833 Medicare Part D claims in 2024 as a Rheumatology Physician in Washington, District of Columbia, prescribing 84% generic.
- 2K
- Part D claims, 2024
- 84%
- generic prescribing
- $11.5K
- industry payments (Sunshine Act)
- ≥83rd
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Saira Bilal, M.D.
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1770899627), first enumerated 08/28/2010.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 1,833 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Practices in an ABMS-board-eligible specialty; board certification not confirmed in federal records.
- Reported
Industry payment transparency
$11.5K in reported industry payments (193 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1770899627 · Rheumatology Physician
NPI-10 · ENUM-MID · TAX-MID · RX-MID · BOOK-THIN · PHOTO-ENUM
- NPI-10 1770899627
- ENUM-MID 2010
- TAX-MID 6K Rheumatology Physician
- RX-MID 1,833
- BOOK-THIN 40 in District of Columbia
- PHOTO-ENUM Erin Scanlon · 2010
Saira Bilal, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
1,833 ≥ 83rd percentile 83% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
◑
Board-eligible specialty (heuristic, not verified)
Saira Bilal, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Saira Bilal, M.D.?
Quality data not reportedPrimary specialty
Rheumatology Physician
Medicare Part D claims
1,833 11% vs specialty avg
Specialty distribution in District of Columbia
How Rheumatology Physician compares to other specialties among District of Columbia providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Rheumatology Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1770899627 |
|---|---|
| Specialty | Rheumatology Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 08/28/2010 |
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Saira Bilal, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$11.5K
Largest payer
Amgen Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Typical
Saira Bilal, M.D. - brand share 16.0%
Rheumatology Physician average
16% brand-name claims vs 84% generic, on 1,833 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
1,833
Total Claims
$2.6M
Total Drug Cost
365
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 4,020.567
- Total Day Supply
- 118,687
- Brand vs Generic
- 16% brand / 84% generic
- Brand Drug Cost
- $2.5M
- Generic Drug Cost
- $46K
- Opioid Claims
- 80 (4.4% rate)
Patient Demographics
- Average Patient Age
- 74.3 years
- Avg HCC Risk Score
- 1.34
- Gender Split
- 69% female / 31% male
- Age Distribution
- <65: 20, 65-74: 172, 75-84: 143, 85+: 30
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Saira Bilal, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2024
- Methotrexate
Methotrexate
371 claims
- Prednisone
Prednisone
245 claims
- Hydroxychloroquine…
Hydroxychloroquine Sulfate
163 claims
- Folic Acid 103
Folic Acid
103 claims
- Duloxetine Hcl 90
Duloxetine Hcl
90 claims
- Alendronate Sodium 67
Alendronate Sodium
67 claims
- Leflunomide 65
Leflunomide
65 claims
- Humira(Cf) Pen 63
Humira(Cf) Pen
63 claims
| Drug | Claims |
|---|---|
| Methotrexate Methotrexate Sodium | 371 |
| Prednisone | 245 |
| Hydroxychloroquine Sulfate | 163 |
| Folic Acid | 103 |
| Duloxetine Hcl | 90 |
| Alendronate Sodium | 67 |
| Leflunomide | 65 |
| Humira(Cf) Pen Adalimumab | 63 |
| Enbrel Sureclick Etanercept | 62 |
| Allopurinol | 61 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Rheumatology Physician Overview
How Saira Bilal, M.D. fits within the Rheumatology Physician landscape nationally.
6,377
Rheumatology Physician Providers in US
52
States with Rheumatology Physician
2,058
Avg Claims per Provider
Saira Bilal, M.D.'s 1,833 claims are below the specialty average of 2,058.
Nationwide Rheumatology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Bilal, both outside District of Columbia so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2010)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Rheumatology Physician Providers in District of Columbia
Other clinicians with the same primary specialty enrolled in District of Columbia, drawn from the same CMS NPPES roster as Bilal.
One of 40 Rheumatology Physician providers enrolled in District of Columbia, 5 are shown here.
Dr. Gelareh Atefi
MD
Washington, DC
Dr. Amarah Baluch
MD
Washington, DC
Dr. Werner Barth
M.D.
Washington, DC
Dr. Adey Berhanu
M.D.
Washington, DC
Dr. Rajkumari Bhagati
MD
Washington, DC
Compare Rheumatology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Saira Bilal, M.D.'s specialty? ▼
Saira Bilal, M.D. specializes in Rheumatology Physician and practices in Washington, District of Columbia. Credentials: M.D..
How much does Saira Bilal, M.D. prescribe under Medicare Part D? ▼
In 2024, Saira Bilal, M.D. wrote 1,833 Medicare Part D claims totaling $2.6M in drug costs for 365 beneficiaries.
Where is Saira Bilal, M.D. located? ▼
Saira Bilal, M.D. is located at 2300 M ST NW, Washington, DC, 20037. Phone: (202) 741-2227.
What is Saira Bilal, M.D.'s NPI number? ▼
Saira Bilal, M.D.'s National Provider Identifier (NPI) is 1770899627, issued on 08/28/2010.
Does Saira Bilal, M.D. prescribe more brand-name or generic drugs? ▼
Saira Bilal, M.D.'s prescribing is 16% brand-name and 84% generic drugs by claim count, with $2.5M in brand drug costs.
Does Saira Bilal, M.D. prescribe opioids? ▼
Yes, Saira Bilal, M.D. had 80 opioid claims in 2024 with an opioid prescribing rate of 4.4%.
How many Rheumatology Physician providers are there in the US? ▼
There are 6,377 Rheumatology Physician providers across 52 states in the US. The average Rheumatology Physician provider writes 2,058 Medicare Part D claims per year.
What drugs does Saira Bilal, M.D. prescribe most often? ▼
Based on 2024 Medicare Part D data, Saira Bilal, M.D.'s most frequently prescribed drugs include Methotrexate, Prednisone, Hydroxychloroquine Sulfate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Saira Bilal, M.D. accept Medicare? ▼
Saira Bilal, M.D. appears in CMS Medicare data with 1,833 Part D claims and 365 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Saira Bilal, M.D.'s credentials? ▼
Saira Bilal, M.D.'s NPI is 1770899627 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.